| Drug Type T cell engagers (TCE) | 
| Synonyms ABS 280, ABS280 | 
| Target- | 
| Action modulators | 
| Mechanism Immunomodulators | 
| Therapeutic Areas | 
| Active Indication | 
| Inactive Indication- | 
| Originator Organization | 
| Active Organization | 
| Inactive Organization- | 
| License Organization- | 
| Drug Highest PhasePreclinical | 
| First Approval Date- | 
| Regulation- | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Solid tumor | Preclinical | United States  | 01 Jul 2025 | 






